Abera’s highly efficient vaccine platform technology, BERA, enables display of antigens at the surface of OMVs.
Abera Bioscience develops a new generation of mucosal vaccines that combine recombinant protein antigens with bacterial outer membrane vesicles (OMVs). The platform is designed to deliver strong immune protection at the body’s mucosal surfaces—the entry point for most respiratory pathogens—while enabling rapid adaptation and scalable manufacturing.
The core of the technology is a standardized OMV particle that serves as a natural adjuvant and antigens presentated on the surface of the OMVs. A modular coupling system allows antigens to be attached efficiently in a plug-and-play manner, making it possible to generate new vaccine candidates quickly in response to emerging pathogens.
Do you find our technology interesting and would you like to discuss a collaboration? Don’t hesitate to contact us.
The OMV backbone is manufactured in a highly controlled process and provides a safe, well-characterized foundation for multiple vaccine programs. Antigens produced in a variety of expression systems can be linked to the OMVs, enabling broad compatibility and efficient development of new candidates as soon as antigen sequences become available.
This modular setup supports fast transitions from pathogen identification to assembled vaccine materials, offering a practical solution for both seasonal diseases and pandemic preparedness.
Respiratory viruses and bacteria typically begin infection in the upper airways. Intranasal OMV-based vaccines activate immunity exactly at these sites, promoting strong IgA responses in the nasal mucosa and systemic IgG responses for broader protection. This early immune activation can reduce transmission. Needle-free intranasal delivery also simplifies vaccination campaigns and improves accessibility across age groups and geographies.
The technology has demonstrated strong preclinical performance in several vaccine candidates, including a serotype-independent pneumococcal vaccine (Ab-01.12) advancing toward Phase 1, an intranasal influenza vaccine showing long-lasting immunity, and exploratory SARS-CoV-2 mucosal vaccine candidates. Across programs, the platform consistently shows durable immune responses and favorable tolerability.
OMV-based vaccines are produced using well-established microbial processes that are widely available in the biopharmaceutical industry. This ensures scalability, cost-effectiveness, and efficient tech transfer to future manufacturing partners.
The platform is compatible with both liquid intranasal formulations and future dry-powder formats that may further simplify storage and delivery.
OMV-based vaccines build on naturally derived and well-understood biological components that have been engineered for consistent performance and a strong safety profile. The vesicles contain no genetic material, are non-replicating, and have a reduced endotoxic footprint, which contributes to their suitability for intranasal administration and broad immunization programs.
At Abera Bioscience, we are committed to revolutionizing vaccine technology with the BERA vaccine platform – a high-density antigen display technology designed for rapid, plug-and-play vaccine development. Our platform excels in creating intranasal vaccines that provide robust mucosal protection. Visit our Projects page for more details on our pipeline.
If you’re interested in collaborating or learning more, contact us at info@aberabio.com.